J. Naylor

发表

Pregnenolone sulphate-independent inhibition of TRPM3 channels by progesterone

C. Fishwick, D. O'regan, K. Porter, 2012, Cell calcium.

Cis‐isomerism and other chemical requirements of steroidal agonists and partial agonists acting at TRPM3 channels

K. Muraki, J. Naylor, S. Jiang, 2010, British journal of pharmacology.

Inhibition of endothelial cell Ca2+ entry and transient receptor potential channels by Sigma-1 receptor ligands

R. Bon, D. O'regan, K. Porter, 2013, British journal of pharmacology.

Function and pharmacology of TRPM3 ion channel

J. Naylor, Jacqueline Naylor, 2008 .

Extracellular Ion Channel Inhibitor Antibodies

D. Beech, J. Naylor, Jacqueline Naylor, 2009 .

Pharmacological antagonism of the incretin system protects against diet-induced obesity

D. D’Alessio, B. Finan, Jonathan E. Campbell, 2019, Molecular metabolism.

Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity

M. Coghlan, D. Baker, J. Trevaskis, 2017, Current opinion in pharmacology.

Use of CRISPR/Cas9-engineered INS-1 pancreatic β cells to define the pharmacology of dual GIPR/GLP-1R agonists.

M. Coghlan, M. Snaith, D. Baker, 2016, The Biochemical journal.

TRPC5 Channel Sensitivities to Antioxidants and Hydroxylated Stilbenes*

D. O'regan, K. Porter, K. Muraki, 2010, The Journal of Biological Chemistry.

Development and characterisation of a novel glucagon like peptide-1 receptor antibody

F. Reimann, F. Gribble, M. Coghlan, 2017, Diabetologia.

Short-Term Stimulation of Calcium-Permeable Transient Receptor Potential Canonical 5-Containing Channels by Oxidized Phospholipids

D. O'regan, K. Porter, C. Milligan, 2010, Arteriosclerosis, thrombosis, and vascular biology.

TRPM3 channel stimulated by pregnenolone sulphate in synovial fibroblasts and negatively coupled to hyaluronan

P. Emery, Coziana Ciurtin, D. Beech, 2010, BMC musculoskeletal disorders.

A Sphingosine-1–Phosphate–Activated Calcium Channel Controlling Vascular Smooth Muscle Cell Motility

A. Cheong, K. Porter, K. Muraki, 2006, Circulation research.

Stereo-selective inhibition of transient receptor potential TRPC5 cation channels by neuroactive steroids

K. Muraki, M. Amer, D. Beech, 2011, British journal of pharmacology.

Use of the Site-Specific Retargeting Jump-In Platform Cell Line to Support Biologic Drug Discovery

Ling Huang, T. Wilkinson, N. Tigue, 2015, Journal of biomolecular screening.

Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease

J. Subramony, P. Tyagi, Yue Huang, 2021, Scientific Reports.

Acoustic Dispensing Preserves the Potency of Therapeutic Peptides throughout the Entire Drug Discovery Workflow

J. Naylor, D. Hornigold, Alessandra Rossi, 2016, Journal of laboratory automation.

Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays.

J. Naylor, D. Hornigold, Christopher Brankin, 2016, Journal of visualized experiments : JoVE.

Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment

J. Osbourn, A. Celeste, C. Rondinone, 2018, Scientific Reports.

GVI phospholipase A2 role in the stimulatory effect of sphingosine-1-phosphate on TRPC5 cationic channels

S. Tumova, D. Beech, Jing Li, 2011, Cell calcium.

Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition

Q. Mo, M. Fukuda, K. Williams, 2019, The Journal of clinical investigation.

TRPC channel activation by extracellular thioredoxin

P. Emery, Coziana Ciurtin, K. Porter, 2008, Nature.

Controlling the bioactivity of a peptide hormone in vivo by reversible self-assembly

David Baker, M. Welland, P. Vicini, 2017, Nature Communications.

Pregnenolone Sulphate- and Cholesterol-Regulated TRPM3 Channels Coupled to Vascular Smooth Muscle Secretion and Contraction

David J Beech, Stephen B Wheatcroft, Bing Hou, 2010, Circulation research.

Rapid and Contrasting Effects of Rosiglitazone on Transient Receptor Potential TRPM3 and TRPC5 Channels

Victoria A. L. Seymour, C. Milligan, D. Beech, 2011, Molecular Pharmacology.

Natural and synthetic flavonoid modulation of TRPC5 channels

Jing Li, Hussein N. Rubaiy, David J Beech, 2016, British journal of pharmacology.

Sensing of Lysophospholipids by TRPC5 Calcium Channel*

David J Beech, K. Muraki, C. Benham, 2006, Journal of Biological Chemistry.

Peptide-YY3-36/glucagon-like peptide-1 combination treatment of obese diabetic mice improves insulin sensitivity associated with recovered pancreatic β-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries

J. Hecksher-Sørensen, O. McGuinness, Jotham Austin, 2021, Molecular metabolism.

Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis.

M. Larsen, O. McGuinness, L. Jermutus, 2020, Nature metabolism.

1086-P: Preclinical Development of an Ultralong-Acting Insulin for Once-Weekly Dosing

C. Rhodes, D. Baker, Victor G. Howard, 2019, Diabetes.

Robotic multiwell planar patch-clamp for native and primary mammalian cells

Mark L Dallas, Jing Li, Chris Peers, 2009, Nature Protocols.

Controlling the bioactivity of a peptide hormone in vivo by reversible self-assembly

David Baker, M. Welland, P. Vicini, 2017, Nature Communications.

Generation of antibodies that are externally acting isoform-specific inhibitors of ion channels.

D. Beech, J. Naylor, Jacqueline Naylor, 2013, Methods in molecular biology.

Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment

J. Osbourn, A. Celeste, C. Rondinone, 2018, Scientific Reports.

Production of a specific extracellular inhibitor of TRPM3 channels

C. Milligan, D. Beech, J. Naylor, 2008, British journal of pharmacology.

Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus

L. Morrow, G. Carlson, P. Ambery, 2018, Diabetologia.